Cubist Systematic Strategies’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$3.7M Sell
102,548
-141,438
-58% -$4.66M 0.02% 1163
2025
Q2
$8.78M Buy
+243,986
New +$9.08M 0.04% 676
2024
Q3
Sell
-679,020
Closed -$14.8M 3493
2024
Q2
$12.1M Sell
679,020
-3,993
-0.6% -$63.7K 0.08% 326
2024
Q1
$10.4M Buy
683,013
+610,280
+839% +$9.72M 0.06% 510
2023
Q4
$1.24M Sell
72,733
-454,755
-86% -$5.29M 0.01% 1879
2023
Q3
$4.41M Buy
527,488
+475,738
+919% +$6.63M 0.03% 836
2023
Q2
$1.29M Sell
51,750
-86,464
-63% -$2.23M 0.01% 1801
2023
Q1
$2.08M Buy
138,214
+103,773
+301% +$1.58M 0.01% 1648
2022
Q4
$407K Sell
34,441
-136,352
-80% -$990K ﹤0.01% 3156
2022
Q3
$1.01M Buy
170,793
+143,001
+515% +$938K 0.01% 2617
2022
Q2
$118K Sell
27,792
-116,494
-81% -$727K ﹤0.01% 3912
2022
Q1
$1.37M Buy
144,286
+122,129
+551% +$1.41M 0.01% 1780
2021
Q4
$421K Buy
+22,157
New +$575K ﹤0.01% 2573
2021
Q3
Sell
-11,000
Closed -$427K 3172
2021
Q2
$427K Buy
11,000
+4,369
+66% +$172K ﹤0.01% 2107
2021
Q1
$320K Sell
6,631
-16,800
-72% -$807K ﹤0.01% 2217
2020
Q4
$1.22M Buy
+23,431
New +$792K 0.02% 1249
2020
Q2
Sell
-18,093
Closed -$178K 2532
2020
Q1
$178K Sell
18,093
-229,271
-93% -$2.9M ﹤0.01% 1780
2019
Q4
$2.75M Buy
247,364
+238,722
+2,762% +$1.82M 0.05% 582
2019
Q3
$49K Buy
8,642
+7,342
+565% +$51.2K ﹤0.01% 2043
2019
Q2
$11K Buy
+1,300
New +$9.83K ﹤0.01% 2404
2018
Q4
Sell
-26,598
Closed -$149K 2281
2018
Q3
$149K Buy
+26,598
New +$304K 0.01% 1502
2018
Q2
Sell
-12,376
Closed -$176K 2044
2018
Q1
$176K Buy
+12,376
New +$158K 0.01% 1453
2017
Q1
Sell
-38,622
Closed -$180K 1864
2016
Q4
$180K Buy
+38,622
New +$226K 0.01% 1303
2015
Q4
Sell
-11,708
Closed -$118K 1943
2015
Q3
$118K Buy
+11,708
New +$174K 0.01% 1594
2015
Q1
Sell
-442
Closed -$7K 2081
2014
Q4
$7K Buy
+442
New +$5.76K ﹤0.01% 1836

Other funds holding TGTX

Cubist Systematic Strategies's TGTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its TG Therapeutics (TGTX) stake by 58% in Q3 2025, selling an estimated $4.66M and leaving 102,548 shares worth $3.7M. The position accounts for 0.02% of the portfolio, ranked #1163.

Cubist Systematic Strategies first reported a position in TGTX in Q4 2014 and has held it in 25 quarters since. The position peaked at $12.1M in Q2 2024. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Cubist Systematic Strategies held 102,548 shares of TG Therapeutics worth $3.7M as of Q3 2025.
  • Cubist Systematic Strategies sold 141,438 TG Therapeutics shares in Q3 2025, an estimated $4.66M.
  • TG Therapeutics made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1163 holding.
  • Cubist Systematic Strategies first reported a position in TG Therapeutics in Q4 2014 and has held it in 25 quarters since.
  • Cubist Systematic Strategies's TG Therapeutics position peaked at $12.1M in Q2 2024.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.